Kennon Heard
Concepts (647)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Acetaminophen | 40 | 2025 | 262 | 8.390 |
Why?
| | Chemical and Drug Induced Liver Injury | 15 | 2023 | 135 | 4.650 |
Why?
| | Analgesics, Non-Narcotic | 21 | 2025 | 125 | 4.490 |
Why?
| | Drug Overdose | 31 | 2025 | 353 | 4.070 |
Why?
| | Poison Control Centers | 13 | 2025 | 79 | 3.470 |
Why?
| | Emergency Service, Hospital | 41 | 2023 | 2172 | 3.250 |
Why?
| | Poisoning | 17 | 2017 | 120 | 2.920 |
Why?
| | Alanine Transaminase | 14 | 2023 | 150 | 2.550 |
Why?
| | Acetylcysteine | 11 | 2023 | 142 | 2.540 |
Why?
| | Cocaine | 10 | 2011 | 173 | 2.370 |
Why?
| | Cannabis | 9 | 2020 | 512 | 2.260 |
Why?
| | Prescription Drugs | 9 | 2018 | 115 | 2.180 |
Why?
| | Antidotes | 9 | 2020 | 140 | 1.480 |
Why?
| | Analgesics, Opioid | 8 | 2023 | 1116 | 1.450 |
Why?
| | Legislation, Drug | 5 | 2017 | 83 | 1.450 |
Why?
| | Cysteine | 4 | 2017 | 205 | 1.330 |
Why?
| | Antipsychotic Agents | 7 | 2019 | 212 | 1.290 |
Why?
| | Marijuana Use | 4 | 2021 | 221 | 1.160 |
Why?
| | Medication Errors | 5 | 2015 | 97 | 1.140 |
Why?
| | Male | 103 | 2022 | 69783 | 1.080 |
Why?
| | Emergency Medicine | 6 | 2019 | 244 | 1.070 |
Why?
| | Pain | 9 | 2020 | 781 | 1.070 |
Why?
| | Humans | 155 | 2025 | 141187 | 1.050 |
Why?
| | Cocaine-Related Disorders | 5 | 2011 | 136 | 1.050 |
Why?
| | Drug Packaging | 2 | 2017 | 43 | 1.040 |
Why?
| | Toxicology | 4 | 2021 | 44 | 1.040 |
Why?
| | Medication Reconciliation | 2 | 2016 | 31 | 0.940 |
Why?
| | Female | 95 | 2022 | 75515 | 0.930 |
Why?
| | Adult | 73 | 2022 | 39177 | 0.920 |
Why?
| | Dose-Response Relationship, Drug | 16 | 2017 | 2064 | 0.920 |
Why?
| | Antidepressive Agents, Tricyclic | 5 | 2014 | 30 | 0.870 |
Why?
| | Spider Bites | 5 | 2019 | 7 | 0.870 |
Why?
| | Antivenins | 5 | 2019 | 28 | 0.870 |
Why?
| | Diphenhydramine | 4 | 2023 | 36 | 0.860 |
Why?
| | Akathisia, Drug-Induced | 2 | 2020 | 6 | 0.840 |
Why?
| | Thiazoles | 4 | 2009 | 126 | 0.830 |
Why?
| | Prescription Drug Monitoring Programs | 1 | 2023 | 14 | 0.810 |
Why?
| | Spider Venoms | 4 | 2019 | 9 | 0.810 |
Why?
| | Benzodiazepines | 6 | 2023 | 156 | 0.800 |
Why?
| | Muscarinic Antagonists | 3 | 2023 | 30 | 0.780 |
Why?
| | Lorazepam | 3 | 2023 | 25 | 0.770 |
Why?
| | Heart Arrest | 8 | 2018 | 385 | 0.760 |
Why?
| | Young Adult | 30 | 2020 | 13673 | 0.750 |
Why?
| | Middle Aged | 54 | 2022 | 34434 | 0.740 |
Why?
| | Seizures | 6 | 2011 | 442 | 0.720 |
Why?
| | Physostigmine | 2 | 2020 | 13 | 0.720 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 2 | 2019 | 348 | 0.720 |
Why?
| | Referral and Consultation | 2 | 2020 | 798 | 0.720 |
Why?
| | Emergency Treatment | 4 | 2015 | 125 | 0.720 |
Why?
| | Black Widow Spider | 4 | 2019 | 7 | 0.710 |
Why?
| | Piperazines | 4 | 2009 | 354 | 0.710 |
Why?
| | Medical History Taking | 3 | 2018 | 116 | 0.700 |
Why?
| | Decision Support Systems, Clinical | 2 | 2023 | 258 | 0.700 |
Why?
| | Dopamine Uptake Inhibitors | 3 | 2011 | 60 | 0.700 |
Why?
| | Delirium | 2 | 2020 | 105 | 0.680 |
Why?
| | Anti-Arrhythmia Agents | 4 | 2014 | 112 | 0.670 |
Why?
| | Abdominal Pain | 2 | 2019 | 145 | 0.660 |
Why?
| | Suicide, Attempted | 5 | 2012 | 393 | 0.640 |
Why?
| | Back Pain | 1 | 2020 | 52 | 0.640 |
Why?
| | Vasoconstrictor Agents | 4 | 2009 | 134 | 0.640 |
Why?
| | Hospitals, Pediatric | 4 | 2018 | 531 | 0.640 |
Why?
| | Free Radical Scavengers | 2 | 2011 | 87 | 0.630 |
Why?
| | Buprenorphine | 2 | 2020 | 179 | 0.610 |
Why?
| | Patient Handoff | 1 | 2020 | 38 | 0.610 |
Why?
| | Retrospective Studies | 31 | 2023 | 16273 | 0.610 |
Why?
| | Haloperidol | 1 | 2019 | 34 | 0.600 |
Why?
| | Ketorolac | 1 | 2019 | 25 | 0.600 |
Why?
| | Emergency Medical Services | 5 | 2025 | 647 | 0.600 |
Why?
| | Social Work | 1 | 2020 | 85 | 0.590 |
Why?
| | Pharmacoepidemiology | 1 | 2018 | 21 | 0.590 |
Why?
| | Gastric Lavage | 3 | 2009 | 9 | 0.570 |
Why?
| | Immunoglobulin Fab Fragments | 4 | 2019 | 59 | 0.570 |
Why?
| | Tertiary Care Centers | 3 | 2017 | 178 | 0.570 |
Why?
| | Vomiting | 6 | 2019 | 129 | 0.560 |
Why?
| | Colorado | 15 | 2021 | 4610 | 0.560 |
Why?
| | Hypotension | 2 | 2022 | 122 | 0.550 |
Why?
| | Prospective Studies | 18 | 2023 | 7739 | 0.550 |
Why?
| | Substance-Related Disorders | 5 | 2012 | 1100 | 0.540 |
Why?
| | Drug Storage | 2 | 2017 | 53 | 0.540 |
Why?
| | Child | 28 | 2023 | 22308 | 0.530 |
Why?
| | Accidents, Home | 1 | 2017 | 33 | 0.530 |
Why?
| | Medical Marijuana | 2 | 2019 | 125 | 0.520 |
Why?
| | Cannabinoids | 3 | 2017 | 178 | 0.520 |
Why?
| | Plant Preparations | 2 | 2015 | 37 | 0.510 |
Why?
| | Fibrin Fibrinogen Degradation Products | 2 | 2007 | 93 | 0.510 |
Why?
| | Calcium Gluconate | 1 | 2016 | 3 | 0.510 |
Why?
| | Electronic Health Records | 4 | 2024 | 1122 | 0.510 |
Why?
| | Pulmonary Embolism | 3 | 2021 | 239 | 0.510 |
Why?
| | Quaternary Ammonium Compounds | 1 | 2016 | 51 | 0.500 |
Why?
| | Hypocalcemia | 1 | 2016 | 35 | 0.490 |
Why?
| | Health Records, Personal | 1 | 2016 | 28 | 0.490 |
Why?
| | Nonprescription Drugs | 4 | 2016 | 66 | 0.490 |
Why?
| | Blood Proteins | 1 | 2017 | 250 | 0.470 |
Why?
| | Mobile Applications | 1 | 2018 | 185 | 0.470 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 5 | 2023 | 256 | 0.470 |
Why?
| | Fat Emulsions, Intravenous | 2 | 2014 | 29 | 0.470 |
Why?
| | Practice Patterns, Physicians' | 3 | 2023 | 1336 | 0.460 |
Why?
| | Antidepressive Agents | 2 | 2012 | 254 | 0.460 |
Why?
| | Liver | 6 | 2022 | 1819 | 0.460 |
Why?
| | Prescription Drug Misuse | 1 | 2015 | 47 | 0.460 |
Why?
| | Electrocardiography | 5 | 2013 | 618 | 0.450 |
Why?
| | Treatment Outcome | 18 | 2020 | 11120 | 0.440 |
Why?
| | Child, Preschool | 13 | 2018 | 11457 | 0.430 |
Why?
| | Asymptomatic Diseases | 2 | 2013 | 92 | 0.420 |
Why?
| | Infant | 12 | 2018 | 9818 | 0.420 |
Why?
| | Crime | 2 | 2011 | 60 | 0.420 |
Why?
| | Observer Variation | 3 | 2010 | 355 | 0.410 |
Why?
| | Adrenergic alpha-2 Receptor Agonists | 1 | 2013 | 24 | 0.410 |
Why?
| | Energy Drinks | 1 | 2013 | 3 | 0.410 |
Why?
| | Performance-Enhancing Substances | 1 | 2013 | 10 | 0.400 |
Why?
| | Arrhythmias, Cardiac | 3 | 2022 | 332 | 0.400 |
Why?
| | Bradycardia | 1 | 2013 | 52 | 0.400 |
Why?
| | Poisons | 2 | 2023 | 20 | 0.400 |
Why?
| | Plasmapheresis | 1 | 2013 | 24 | 0.400 |
Why?
| | Diet Surveys | 1 | 2013 | 91 | 0.400 |
Why?
| | Accidents | 1 | 2013 | 45 | 0.400 |
Why?
| | Double-Blind Method | 7 | 2020 | 1983 | 0.400 |
Why?
| | Adolescent | 27 | 2020 | 22007 | 0.390 |
Why?
| | Hematemesis | 1 | 2012 | 3 | 0.390 |
Why?
| | Amphotericin B | 1 | 2013 | 36 | 0.390 |
Why?
| | beta-Alanine | 1 | 2012 | 17 | 0.390 |
Why?
| | Aspartate Aminotransferases | 3 | 2010 | 86 | 0.390 |
Why?
| | Foreign Bodies | 2 | 2011 | 107 | 0.390 |
Why?
| | Stomach Diseases | 1 | 2012 | 19 | 0.390 |
Why?
| | Phytotherapy | 1 | 2013 | 82 | 0.390 |
Why?
| | Ethers | 1 | 2012 | 19 | 0.390 |
Why?
| | Sulfonylurea Compounds | 2 | 2010 | 49 | 0.380 |
Why?
| | Citalopram | 1 | 2012 | 35 | 0.380 |
Why?
| | Liver Function Tests | 7 | 2020 | 105 | 0.370 |
Why?
| | Antithrombins | 1 | 2012 | 64 | 0.370 |
Why?
| | Drug Administration Schedule | 5 | 2014 | 771 | 0.370 |
Why?
| | Propafenone | 1 | 2011 | 2 | 0.370 |
Why?
| | Antifungal Agents | 1 | 2013 | 144 | 0.370 |
Why?
| | Thiophenes | 1 | 2012 | 122 | 0.370 |
Why?
| | Genetic Predisposition to Disease | 1 | 2020 | 2363 | 0.360 |
Why?
| | C-Peptide | 2 | 2010 | 167 | 0.360 |
Why?
| | Firesetting Behavior | 1 | 2011 | 1 | 0.360 |
Why?
| | Anaphylaxis | 2 | 2012 | 107 | 0.360 |
Why?
| | Aged | 27 | 2019 | 24574 | 0.360 |
Why?
| | Disease Models, Animal | 9 | 2011 | 4404 | 0.360 |
Why?
| | Clinical Enzyme Tests | 2 | 2013 | 10 | 0.360 |
Why?
| | Infusions, Intravenous | 6 | 2013 | 417 | 0.350 |
Why?
| | Dronabinol | 4 | 2021 | 243 | 0.350 |
Why?
| | Charcoal | 4 | 2006 | 27 | 0.350 |
Why?
| | Benzimidazoles | 1 | 2012 | 182 | 0.350 |
Why?
| | Alcohol Drinking | 4 | 2012 | 834 | 0.350 |
Why?
| | Temperance | 2 | 2010 | 21 | 0.350 |
Why?
| | Administration, Intravenous | 4 | 2016 | 161 | 0.350 |
Why?
| | Chemical and Drug Induced Liver Injury, Chronic | 1 | 2011 | 11 | 0.350 |
Why?
| | Opioid-Related Disorders | 2 | 2020 | 562 | 0.340 |
Why?
| | Cholinergic Antagonists | 1 | 2011 | 24 | 0.340 |
Why?
| | Brain Edema | 1 | 2011 | 64 | 0.340 |
Why?
| | Amitriptyline | 2 | 2001 | 22 | 0.340 |
Why?
| | Evidence-Based Medicine | 4 | 2023 | 750 | 0.340 |
Why?
| | Blood Chemical Analysis | 3 | 2021 | 110 | 0.340 |
Why?
| | Reproducibility of Results | 6 | 2024 | 3348 | 0.330 |
Why?
| | Tachycardia, Ventricular | 1 | 2012 | 175 | 0.330 |
Why?
| | Self-Injurious Behavior | 1 | 2012 | 139 | 0.330 |
Why?
| | Aged, 80 and over | 15 | 2018 | 7856 | 0.330 |
Why?
| | Burns | 2 | 2015 | 349 | 0.330 |
Why?
| | Immunologic Factors | 2 | 2019 | 248 | 0.330 |
Why?
| | Liver Failure | 1 | 2011 | 80 | 0.330 |
Why?
| | Hydrofluoric Acid | 2 | 2016 | 6 | 0.330 |
Why?
| | Pharmaceutical Vehicles | 1 | 2010 | 12 | 0.320 |
Why?
| | Propylene Glycol | 1 | 2010 | 9 | 0.320 |
Why?
| | Barium | 1 | 2009 | 26 | 0.320 |
Why?
| | Population Surveillance | 1 | 2013 | 481 | 0.320 |
Why?
| | Time Factors | 12 | 2020 | 6956 | 0.320 |
Why?
| | Explosive Agents | 1 | 2009 | 7 | 0.320 |
Why?
| | Hypokalemia | 1 | 2009 | 24 | 0.320 |
Why?
| | Imines | 2 | 2022 | 8 | 0.310 |
Why?
| | United States | 18 | 2025 | 15220 | 0.310 |
Why?
| | Warfarin | 1 | 2010 | 153 | 0.310 |
Why?
| | Acidosis, Lactic | 1 | 2010 | 46 | 0.310 |
Why?
| | Liver Diseases, Alcoholic | 2 | 2007 | 94 | 0.310 |
Why?
| | Emetics | 2 | 2006 | 7 | 0.310 |
Why?
| | Deception | 1 | 2009 | 20 | 0.310 |
Why?
| | Iatrogenic Disease | 1 | 2010 | 71 | 0.310 |
Why?
| | Random Allocation | 3 | 2007 | 367 | 0.300 |
Why?
| | Benzoquinones | 2 | 2022 | 48 | 0.300 |
Why?
| | Cross-Sectional Studies | 9 | 2020 | 5636 | 0.300 |
Why?
| | Risk Assessment | 8 | 2017 | 3490 | 0.290 |
Why?
| | Surveys and Questionnaires | 4 | 2018 | 5929 | 0.290 |
Why?
| | Risk Factors | 9 | 2017 | 10438 | 0.290 |
Why?
| | Odds Ratio | 7 | 2017 | 1052 | 0.290 |
Why?
| | Fluorides | 2 | 2016 | 49 | 0.290 |
Why?
| | Oximetry | 1 | 2009 | 127 | 0.290 |
Why?
| | Hypothermia, Induced | 1 | 2009 | 92 | 0.290 |
Why?
| | Length of Stay | 3 | 2020 | 1254 | 0.290 |
Why?
| | Cyanoacrylates | 1 | 2008 | 4 | 0.280 |
Why?
| | Eyelashes | 1 | 2008 | 4 | 0.280 |
Why?
| | Adhesives | 1 | 2008 | 14 | 0.280 |
Why?
| | Reference Values | 4 | 2017 | 805 | 0.280 |
Why?
| | Detergents | 1 | 2008 | 45 | 0.280 |
Why?
| | Intellectual Disability | 1 | 2009 | 172 | 0.280 |
Why?
| | Point-of-Care Systems | 1 | 2010 | 185 | 0.280 |
Why?
| | Hypoglycemia | 2 | 2010 | 463 | 0.270 |
Why?
| | Cardiovascular System | 1 | 2009 | 137 | 0.270 |
Why?
| | Alcoholism | 4 | 2023 | 821 | 0.270 |
Why?
| | Publishing | 1 | 2009 | 145 | 0.270 |
Why?
| | Animals | 22 | 2019 | 37657 | 0.270 |
Why?
| | Brugada Syndrome | 1 | 2007 | 14 | 0.270 |
Why?
| | Polyethylene Glycols | 1 | 2012 | 638 | 0.270 |
Why?
| | Diazepam | 1 | 2007 | 35 | 0.270 |
Why?
| | Niacin | 1 | 2007 | 17 | 0.270 |
Why?
| | Clinical Laboratory Techniques | 1 | 2008 | 96 | 0.260 |
Why?
| | Mice, Inbred Strains | 4 | 2009 | 412 | 0.260 |
Why?
| | Vitamin B Complex | 1 | 2007 | 41 | 0.260 |
Why?
| | Pediatrics | 1 | 2015 | 1094 | 0.250 |
Why?
| | Thromboembolism | 1 | 2007 | 118 | 0.250 |
Why?
| | Brain Infarction | 1 | 2006 | 23 | 0.250 |
Why?
| | Specimen Handling | 1 | 2008 | 182 | 0.250 |
Why?
| | Hypoxia-Ischemia, Brain | 1 | 2006 | 41 | 0.240 |
Why?
| | Nausea | 4 | 2014 | 111 | 0.240 |
Why?
| | Analgesics | 4 | 2017 | 226 | 0.240 |
Why?
| | Decontamination | 1 | 2006 | 32 | 0.240 |
Why?
| | Amiodarone | 1 | 2005 | 27 | 0.240 |
Why?
| | Self Report | 4 | 2021 | 856 | 0.240 |
Why?
| | Anticoagulants | 1 | 2010 | 675 | 0.240 |
Why?
| | Age Factors | 7 | 2017 | 3292 | 0.230 |
Why?
| | Intention | 1 | 2007 | 178 | 0.230 |
Why?
| | Vasospasm, Intracranial | 1 | 2005 | 18 | 0.230 |
Why?
| | Venous Thrombosis | 1 | 2007 | 192 | 0.230 |
Why?
| | Epilepsy | 2 | 2020 | 349 | 0.230 |
Why?
| | Eating | 4 | 2017 | 392 | 0.230 |
Why?
| | Sodium Nitrite | 1 | 2005 | 39 | 0.230 |
Why?
| | Randomized Controlled Trials as Topic | 5 | 2012 | 1556 | 0.230 |
Why?
| | Drug Utilization | 5 | 2014 | 169 | 0.230 |
Why?
| | Calcium | 3 | 2016 | 1187 | 0.230 |
Why?
| | Subarachnoid Hemorrhage | 1 | 2005 | 70 | 0.220 |
Why?
| | Education, Medical | 2 | 2021 | 270 | 0.220 |
Why?
| | Diagnostic Imaging | 1 | 2007 | 326 | 0.220 |
Why?
| | Acute Kidney Injury | 1 | 2012 | 819 | 0.220 |
Why?
| | Coma | 2 | 2006 | 35 | 0.220 |
Why?
| | Databases, Factual | 1 | 2010 | 1444 | 0.220 |
Why?
| | Biomarkers | 7 | 2021 | 4174 | 0.210 |
Why?
| | Hospitals, Urban | 5 | 2021 | 137 | 0.210 |
Why?
| | Injections, Intraperitoneal | 4 | 2009 | 114 | 0.210 |
Why?
| | Anti-Anxiety Agents | 2 | 2020 | 43 | 0.200 |
Why?
| | Triage | 2 | 2025 | 246 | 0.200 |
Why?
| | Animal Experimentation | 1 | 2003 | 9 | 0.200 |
Why?
| | Case-Control Studies | 4 | 2022 | 3588 | 0.200 |
Why?
| | Hypoglycemic Agents | 2 | 2010 | 1365 | 0.200 |
Why?
| | Glasgow Coma Scale | 1 | 2004 | 203 | 0.200 |
Why?
| | Calcium Chloride | 1 | 2003 | 11 | 0.200 |
Why?
| | Sensitivity and Specificity | 5 | 2010 | 1973 | 0.200 |
Why?
| | Insulin | 3 | 2019 | 2482 | 0.200 |
Why?
| | Hospitals, Teaching | 3 | 2014 | 115 | 0.200 |
Why?
| | Fibrinolytic Agents | 2 | 2021 | 283 | 0.200 |
Why?
| | Magnesium Sulfate | 1 | 2003 | 19 | 0.200 |
Why?
| | Documentation | 1 | 2024 | 199 | 0.190 |
Why?
| | Placebos | 2 | 2014 | 198 | 0.190 |
Why?
| | Umbilical Cord | 2 | 2021 | 87 | 0.190 |
Why?
| | Desipramine | 1 | 2001 | 11 | 0.180 |
Why?
| | Longevity | 3 | 2009 | 175 | 0.180 |
Why?
| | Phenylurea Compounds | 1 | 2022 | 95 | 0.180 |
Why?
| | Logistic Models | 3 | 2017 | 2086 | 0.180 |
Why?
| | Confidence Intervals | 4 | 2010 | 329 | 0.180 |
Why?
| | Cardiopulmonary Resuscitation | 3 | 2018 | 326 | 0.180 |
Why?
| | Substance Withdrawal Syndrome | 1 | 2023 | 184 | 0.180 |
Why?
| | Severity of Illness Index | 1 | 2009 | 2892 | 0.170 |
Why?
| | Sinus Thrombosis, Intracranial | 1 | 2021 | 23 | 0.170 |
Why?
| | Narcotic Antagonists | 2 | 2020 | 187 | 0.170 |
Why?
| | Hyperthermia, Induced | 1 | 2022 | 120 | 0.170 |
Why?
| | Research Design | 3 | 2006 | 1143 | 0.170 |
Why?
| | Fractures, Bone | 2 | 2017 | 404 | 0.170 |
Why?
| | Heart Atria | 1 | 2001 | 139 | 0.170 |
Why?
| | Opiate Substitution Treatment | 2 | 2020 | 166 | 0.170 |
Why?
| | Acute Disease | 2 | 2019 | 1008 | 0.170 |
Why?
| | Myocardial Contraction | 1 | 2001 | 303 | 0.160 |
Why?
| | Immunoglobulin Fragments | 1 | 1999 | 12 | 0.160 |
Why?
| | Droperidol | 1 | 1999 | 5 | 0.160 |
Why?
| | Lysergic Acid Diethylamide | 1 | 1999 | 3 | 0.160 |
Why?
| | Lithium Carbonate | 1 | 1999 | 6 | 0.160 |
Why?
| | Serotonin Syndrome | 1 | 1999 | 4 | 0.160 |
Why?
| | Wisconsin | 1 | 2020 | 101 | 0.160 |
Why?
| | Serotonin Receptor Agonists | 1 | 1999 | 26 | 0.160 |
Why?
| | Starch | 1 | 2019 | 22 | 0.160 |
Why?
| | Scorpion Stings | 1 | 1999 | 1 | 0.160 |
Why?
| | Survival Analysis | 4 | 2010 | 1319 | 0.160 |
Why?
| | Nutritive Value | 1 | 2019 | 37 | 0.160 |
Why?
| | Healthy Volunteers | 2 | 2019 | 214 | 0.150 |
Why?
| | Ventricular Premature Complexes | 1 | 1999 | 36 | 0.150 |
Why?
| | Geriatric Assessment | 2 | 2011 | 221 | 0.150 |
Why?
| | Snake Bites | 1 | 1999 | 23 | 0.150 |
Why?
| | Administration, Oral | 4 | 2019 | 803 | 0.150 |
Why?
| | Thrombocytopenia | 1 | 2021 | 208 | 0.150 |
Why?
| | Immune System | 1 | 2020 | 183 | 0.150 |
Why?
| | Fallopian Tube Diseases | 1 | 1998 | 4 | 0.150 |
Why?
| | Community Health Workers | 1 | 2020 | 75 | 0.150 |
Why?
| | Pregnancy, Tubal | 1 | 1998 | 5 | 0.150 |
Why?
| | Abortifacient Agents, Nonsteroidal | 1 | 1998 | 20 | 0.150 |
Why?
| | Munchausen Syndrome by Proxy | 1 | 1998 | 2 | 0.150 |
Why?
| | Metabolome | 1 | 2022 | 366 | 0.150 |
Why?
| | Dietary Carbohydrates | 1 | 2019 | 153 | 0.150 |
Why?
| | Drug Therapy, Combination | 4 | 2011 | 1040 | 0.140 |
Why?
| | Mass Screening | 1 | 2007 | 1310 | 0.140 |
Why?
| | Chi-Square Distribution | 2 | 2017 | 521 | 0.140 |
Why?
| | Plant Extracts | 1 | 2020 | 209 | 0.140 |
Why?
| | Cohort Studies | 7 | 2023 | 5799 | 0.140 |
Why?
| | Cannabidiol | 1 | 2020 | 125 | 0.140 |
Why?
| | Anticonvulsants | 1 | 2020 | 225 | 0.140 |
Why?
| | Sex Factors | 5 | 2022 | 2058 | 0.140 |
Why?
| | Sulfasalazine | 1 | 1998 | 23 | 0.140 |
Why?
| | Drug Antagonism | 2 | 2009 | 10 | 0.140 |
Why?
| | Dietary Fats | 1 | 2019 | 300 | 0.140 |
Why?
| | Faculty, Medical | 1 | 2021 | 295 | 0.140 |
Why?
| | Drug Interactions | 4 | 2014 | 406 | 0.140 |
Why?
| | Genome-Wide Association Study | 2 | 2023 | 1402 | 0.140 |
Why?
| | Dyspnea | 1 | 1999 | 257 | 0.130 |
Why?
| | Methotrexate | 1 | 1998 | 255 | 0.130 |
Why?
| | Peptide Fragments | 1 | 2021 | 698 | 0.130 |
Why?
| | Gastrointestinal Agents | 1 | 1998 | 67 | 0.130 |
Why?
| | Continuity of Patient Care | 1 | 2020 | 287 | 0.130 |
Why?
| | Fellowships and Scholarships | 1 | 2021 | 319 | 0.130 |
Why?
| | Incidence | 4 | 2013 | 2794 | 0.130 |
Why?
| | Out-of-Hospital Cardiac Arrest | 1 | 2018 | 121 | 0.130 |
Why?
| | Survival Rate | 3 | 2013 | 1970 | 0.130 |
Why?
| | Mice | 8 | 2009 | 18048 | 0.130 |
Why?
| | Ammonium Compounds | 1 | 2016 | 3 | 0.130 |
Why?
| | Energy Intake | 1 | 2019 | 513 | 0.130 |
Why?
| | Simulation Training | 1 | 2018 | 127 | 0.120 |
Why?
| | Cytochrome P-450 CYP2E1 Inhibitors | 1 | 2016 | 2 | 0.120 |
Why?
| | Prenatal Care | 1 | 2019 | 303 | 0.120 |
Why?
| | Metabolic Clearance Rate | 2 | 2019 | 116 | 0.120 |
Why?
| | Ventricular Fibrillation | 1 | 2016 | 62 | 0.120 |
Why?
| | Half-Life | 2 | 2019 | 146 | 0.120 |
Why?
| | Clinical Trials as Topic | 2 | 2012 | 1052 | 0.120 |
Why?
| | Hypnotics and Sedatives | 1 | 1998 | 214 | 0.120 |
Why?
| | Pain Management | 2 | 2017 | 396 | 0.120 |
Why?
| | Pharmacovigilance | 1 | 2015 | 24 | 0.120 |
Why?
| | Milk | 1 | 2016 | 123 | 0.120 |
Why?
| | Predictive Value of Tests | 3 | 2015 | 2070 | 0.120 |
Why?
| | Genetic Variation | 1 | 2020 | 1000 | 0.120 |
Why?
| | Herniorrhaphy | 1 | 2016 | 76 | 0.120 |
Why?
| | Fatal Outcome | 2 | 2013 | 309 | 0.110 |
Why?
| | Adverse Drug Reaction Reporting Systems | 1 | 2015 | 81 | 0.110 |
Why?
| | Hemodialysis Units, Hospital | 1 | 1994 | 5 | 0.110 |
Why?
| | Pilot Projects | 1 | 2020 | 1820 | 0.110 |
Why?
| | Child Behavior | 1 | 2017 | 251 | 0.110 |
Why?
| | Ondansetron | 1 | 2014 | 19 | 0.110 |
Why?
| | Liver Failure, Acute | 1 | 2015 | 64 | 0.110 |
Why?
| | Models, Biological | 2 | 2015 | 1828 | 0.110 |
Why?
| | Patient Simulation | 1 | 2014 | 37 | 0.110 |
Why?
| | Total Quality Management | 1 | 1994 | 61 | 0.110 |
Why?
| | Cytochrome P-450 CYP2D6 | 1 | 2014 | 32 | 0.110 |
Why?
| | Hydrocodone | 1 | 2014 | 18 | 0.110 |
Why?
| | Personnel Staffing and Scheduling | 1 | 2015 | 96 | 0.110 |
Why?
| | Transaminases | 1 | 2014 | 23 | 0.110 |
Why?
| | Oxycodone | 1 | 2014 | 48 | 0.110 |
Why?
| | Curriculum | 1 | 2021 | 1033 | 0.100 |
Why?
| | Guanfacine | 1 | 2013 | 5 | 0.100 |
Why?
| | Physicians | 2 | 2020 | 934 | 0.100 |
Why?
| | Clonidine | 1 | 2013 | 34 | 0.100 |
Why?
| | International Normalized Ratio | 2 | 2011 | 47 | 0.100 |
Why?
| | Remote Consultation | 1 | 2014 | 59 | 0.100 |
Why?
| | Prognosis | 3 | 2011 | 4073 | 0.100 |
Why?
| | Cesium | 1 | 2013 | 20 | 0.100 |
Why?
| | Vitamins | 1 | 2015 | 184 | 0.100 |
Why?
| | Internship and Residency | 2 | 2014 | 1235 | 0.100 |
Why?
| | Indazoles | 1 | 2014 | 67 | 0.100 |
Why?
| | Food | 1 | 2015 | 163 | 0.100 |
Why?
| | Acute Pain | 1 | 2014 | 55 | 0.100 |
Why?
| | Pregnancy Complications | 1 | 2019 | 587 | 0.100 |
Why?
| | Deoxycholic Acid | 1 | 2013 | 17 | 0.100 |
Why?
| | Lethargy | 1 | 2012 | 4 | 0.100 |
Why?
| | Duloxetine Hydrochloride | 1 | 2012 | 13 | 0.100 |
Why?
| | Dabigatran | 1 | 2012 | 23 | 0.100 |
Why?
| | Pain Measurement | 4 | 2019 | 554 | 0.100 |
Why?
| | Walking | 1 | 2017 | 543 | 0.100 |
Why?
| | Canada | 2 | 2025 | 428 | 0.100 |
Why?
| | Tachycardia | 1 | 2012 | 55 | 0.100 |
Why?
| | Chlorides | 1 | 2013 | 138 | 0.100 |
Why?
| | Sleep Stages | 1 | 2012 | 76 | 0.090 |
Why?
| | Sulfhydryl Reagents | 1 | 2012 | 12 | 0.090 |
Why?
| | Pyrazoles | 1 | 2016 | 443 | 0.090 |
Why?
| | Attitude of Health Personnel | 1 | 2020 | 1171 | 0.090 |
Why?
| | Data Collection | 2 | 2013 | 661 | 0.090 |
Why?
| | Marijuana Abuse | 1 | 2015 | 231 | 0.090 |
Why?
| | Mycoses | 1 | 2013 | 85 | 0.090 |
Why?
| | Dizziness | 1 | 2012 | 83 | 0.090 |
Why?
| | Sampling Studies | 1 | 2012 | 102 | 0.090 |
Why?
| | Arsenicals | 1 | 2012 | 30 | 0.090 |
Why?
| | Magnesium | 2 | 2004 | 157 | 0.090 |
Why?
| | Athletic Performance | 1 | 2013 | 81 | 0.090 |
Why?
| | Patient Discharge | 2 | 2016 | 932 | 0.090 |
Why?
| | Accidental Falls | 2 | 2011 | 198 | 0.090 |
Why?
| | Drug Combinations | 1 | 2013 | 358 | 0.090 |
Why?
| | Information Systems | 1 | 2011 | 61 | 0.090 |
Why?
| | Sulfides | 1 | 2012 | 82 | 0.090 |
Why?
| | Arabia | 1 | 2011 | 2 | 0.090 |
Why?
| | Levamisole | 1 | 2011 | 19 | 0.090 |
Why?
| | Follow-Up Studies | 3 | 2010 | 5200 | 0.090 |
Why?
| | Immunocompromised Host | 1 | 2013 | 203 | 0.090 |
Why?
| | Marijuana Smoking | 1 | 2015 | 263 | 0.090 |
Why?
| | Hepatic Encephalopathy | 1 | 2011 | 25 | 0.090 |
Why?
| | Laparoscopy | 1 | 2016 | 463 | 0.090 |
Why?
| | Drug Contamination | 1 | 2011 | 52 | 0.090 |
Why?
| | Structure-Activity Relationship | 1 | 2012 | 579 | 0.090 |
Why?
| | Molecular Structure | 1 | 2012 | 503 | 0.090 |
Why?
| | Pharmacogenetics | 1 | 2012 | 167 | 0.080 |
Why?
| | Dietary Supplements | 1 | 2015 | 566 | 0.080 |
Why?
| | Sports | 1 | 2013 | 219 | 0.080 |
Why?
| | Universities | 1 | 2013 | 452 | 0.080 |
Why?
| | Glipizide | 1 | 2010 | 6 | 0.080 |
Why?
| | Laboratories, Hospital | 1 | 2010 | 12 | 0.080 |
Why?
| | Hepatitis, Alcoholic | 1 | 2010 | 14 | 0.080 |
Why?
| | Troponin | 1 | 2010 | 51 | 0.080 |
Why?
| | Glyburide | 1 | 2010 | 32 | 0.080 |
Why?
| | Crowding | 1 | 2010 | 37 | 0.080 |
Why?
| | Drug Prescriptions | 2 | 2016 | 262 | 0.080 |
Why?
| | Biological Availability | 2 | 2019 | 137 | 0.080 |
Why?
| | Body Weight | 1 | 2014 | 996 | 0.080 |
Why?
| | Watchful Waiting | 1 | 2010 | 84 | 0.080 |
Why?
| | Adjuvants, Immunologic | 1 | 2011 | 238 | 0.080 |
Why?
| | Quetiapine Fumarate | 1 | 2009 | 24 | 0.080 |
Why?
| | Dibenzothiazepines | 1 | 2009 | 18 | 0.080 |
Why?
| | Risperidone | 1 | 2009 | 30 | 0.080 |
Why?
| | Aripiprazole | 1 | 2009 | 21 | 0.080 |
Why?
| | Potassium | 1 | 2009 | 148 | 0.080 |
Why?
| | Role | 1 | 2009 | 30 | 0.080 |
Why?
| | Efficiency, Organizational | 1 | 2010 | 139 | 0.070 |
Why?
| | Head Protective Devices | 1 | 2009 | 25 | 0.070 |
Why?
| | Dogs | 1 | 2010 | 427 | 0.070 |
Why?
| | Quality Control | 1 | 2009 | 171 | 0.070 |
Why?
| | Acidosis | 2 | 2006 | 102 | 0.070 |
Why?
| | Glutathione | 3 | 2022 | 356 | 0.070 |
Why?
| | Bibliometrics | 1 | 2009 | 65 | 0.070 |
Why?
| | Verapamil | 2 | 2014 | 40 | 0.070 |
Why?
| | Diarrhea | 1 | 2009 | 183 | 0.070 |
Why?
| | Body Temperature | 1 | 2009 | 224 | 0.070 |
Why?
| | Renal Dialysis | 1 | 2013 | 457 | 0.070 |
Why?
| | Intensive Care Units, Pediatric | 1 | 2011 | 270 | 0.070 |
Why?
| | Quality Indicators, Health Care | 1 | 2011 | 308 | 0.070 |
Why?
| | Workload | 1 | 2010 | 166 | 0.070 |
Why?
| | Skiing | 1 | 2009 | 51 | 0.070 |
Why?
| | Pharmacy Service, Hospital | 1 | 2009 | 87 | 0.070 |
Why?
| | Bacitracin | 1 | 2008 | 5 | 0.070 |
Why?
| | Hair Preparations | 1 | 2008 | 2 | 0.070 |
Why?
| | Adhesiveness | 1 | 2008 | 20 | 0.070 |
Why?
| | Acetone | 1 | 2008 | 12 | 0.070 |
Why?
| | Propylene Glycols | 1 | 2008 | 28 | 0.070 |
Why?
| | Informed Consent | 2 | 2006 | 189 | 0.070 |
Why?
| | Nylons | 1 | 2008 | 22 | 0.070 |
Why?
| | Equipment Design | 1 | 2009 | 525 | 0.070 |
Why?
| | Cause of Death | 1 | 2010 | 440 | 0.070 |
Why?
| | Withholding Treatment | 1 | 2008 | 78 | 0.070 |
Why?
| | Glycerol | 1 | 2008 | 91 | 0.070 |
Why?
| | Health Services Accessibility | 1 | 2015 | 1016 | 0.070 |
Why?
| | Cellulose | 1 | 2008 | 60 | 0.070 |
Why?
| | Students | 1 | 2013 | 645 | 0.070 |
Why?
| | Nephelometry and Turbidimetry | 1 | 2007 | 15 | 0.070 |
Why?
| | Drug Synergism | 1 | 2008 | 375 | 0.070 |
Why?
| | Military Personnel | 1 | 2014 | 613 | 0.070 |
Why?
| | Quinolones | 1 | 2009 | 147 | 0.070 |
Why?
| | Laboratories | 1 | 2008 | 110 | 0.070 |
Why?
| | Polypharmacy | 1 | 2008 | 89 | 0.060 |
Why?
| | Substance Abuse Detection | 2 | 2021 | 104 | 0.060 |
Why?
| | Tissue Distribution | 2 | 2019 | 330 | 0.060 |
Why?
| | Phosphates | 1 | 2008 | 181 | 0.060 |
Why?
| | Formates | 1 | 2006 | 14 | 0.060 |
Why?
| | Research | 2 | 2011 | 455 | 0.060 |
Why?
| | Defibrillators | 1 | 2006 | 22 | 0.060 |
Why?
| | Combined Modality Therapy | 1 | 2009 | 1243 | 0.060 |
Why?
| | Methanol | 1 | 2006 | 43 | 0.060 |
Why?
| | Periodicals as Topic | 1 | 2009 | 217 | 0.060 |
Why?
| | Kidney Transplantation | 1 | 2013 | 675 | 0.060 |
Why?
| | Vasopressins | 1 | 2006 | 60 | 0.060 |
Why?
| | Statistics, Nonparametric | 1 | 2007 | 434 | 0.060 |
Why?
| | Blindness | 1 | 2006 | 48 | 0.060 |
Why?
| | Probability | 2 | 2010 | 309 | 0.060 |
Why?
| | Spinal Diseases | 1 | 2006 | 51 | 0.060 |
Why?
| | Naproxen | 1 | 2006 | 17 | 0.060 |
Why?
| | Health Services for the Aged | 1 | 2006 | 73 | 0.060 |
Why?
| | Ipecac | 1 | 2005 | 8 | 0.060 |
Why?
| | Epinephrine | 1 | 2006 | 146 | 0.060 |
Why?
| | Hospitalization | 2 | 2011 | 2255 | 0.060 |
Why?
| | Respiratory Insufficiency | 1 | 2009 | 326 | 0.060 |
Why?
| | Aging | 2 | 2014 | 1892 | 0.060 |
Why?
| | Population Dynamics | 1 | 2006 | 153 | 0.060 |
Why?
| | Ibuprofen | 1 | 2006 | 83 | 0.060 |
Why?
| | Hospitals, University | 1 | 2006 | 175 | 0.060 |
Why?
| | Haplorhini | 1 | 2005 | 53 | 0.060 |
Why?
| | Telemedicine | 1 | 2014 | 891 | 0.060 |
Why?
| | Premedication | 1 | 2005 | 41 | 0.060 |
Why?
| | Geriatrics | 1 | 2006 | 93 | 0.060 |
Why?
| | Practice Guidelines as Topic | 2 | 2014 | 1597 | 0.060 |
Why?
| | Respiration, Artificial | 1 | 2009 | 683 | 0.060 |
Why?
| | Risk | 1 | 2007 | 904 | 0.060 |
Why?
| | Spine | 1 | 2006 | 180 | 0.050 |
Why?
| | Single-Blind Method | 1 | 2005 | 288 | 0.050 |
Why?
| | Water | 1 | 2008 | 464 | 0.050 |
Why?
| | Fluoride Poisoning | 1 | 2004 | 3 | 0.050 |
Why?
| | Phenobarbital | 1 | 2023 | 18 | 0.050 |
Why?
| | Motivation | 1 | 2009 | 602 | 0.050 |
Why?
| | Resuscitation | 1 | 2006 | 278 | 0.050 |
Why?
| | Blood Glucose | 2 | 2019 | 2269 | 0.050 |
Why?
| | Guidelines as Topic | 1 | 2005 | 273 | 0.050 |
Why?
| | Hydroxyzine | 1 | 2023 | 4 | 0.050 |
Why?
| | Maltose | 1 | 2023 | 8 | 0.050 |
Why?
| | Delphi Technique | 1 | 2025 | 308 | 0.050 |
Why?
| | Mycophenolic Acid | 1 | 2004 | 118 | 0.050 |
Why?
| | Health Policy | 1 | 2006 | 403 | 0.050 |
Why?
| | Sheep | 1 | 2006 | 874 | 0.050 |
Why?
| | Survival | 1 | 2003 | 39 | 0.050 |
Why?
| | Urea | 1 | 2023 | 81 | 0.050 |
Why?
| | Aspirin | 1 | 2006 | 385 | 0.050 |
Why?
| | Patient Participation | 1 | 2006 | 432 | 0.050 |
Why?
| | Pregnancy | 3 | 2021 | 7070 | 0.050 |
Why?
| | Lactates | 1 | 2022 | 85 | 0.050 |
Why?
| | Internet | 1 | 2007 | 690 | 0.050 |
Why?
| | Sex Distribution | 2 | 2015 | 379 | 0.050 |
Why?
| | Culture Techniques | 1 | 2001 | 74 | 0.050 |
Why?
| | Urban Population | 2 | 2019 | 485 | 0.050 |
Why?
| | Prevalence | 3 | 2015 | 2772 | 0.050 |
Why?
| | Blood Physiological Phenomena | 1 | 2021 | 13 | 0.040 |
Why?
| | Consensus | 1 | 2025 | 704 | 0.040 |
Why?
| | Neural Conduction | 1 | 2001 | 90 | 0.040 |
Why?
| | Hirudins | 1 | 2021 | 52 | 0.040 |
Why?
| | Academic Medical Centers | 2 | 2016 | 528 | 0.040 |
Why?
| | Breast Neoplasms | 1 | 2013 | 2250 | 0.040 |
Why?
| | Calcium Channel Blockers | 1 | 2001 | 172 | 0.040 |
Why?
| | Controlled Clinical Trials as Topic | 1 | 2020 | 28 | 0.040 |
Why?
| | Infusions, Parenteral | 1 | 2020 | 43 | 0.040 |
Why?
| | Pirenzepine | 1 | 1999 | 8 | 0.040 |
Why?
| | Scorpions | 1 | 1999 | 3 | 0.040 |
Why?
| | South America | 1 | 1999 | 60 | 0.040 |
Why?
| | Blood Cell Count | 2 | 2013 | 54 | 0.040 |
Why?
| | Certification | 1 | 2020 | 118 | 0.040 |
Why?
| | Narcotics | 1 | 1999 | 55 | 0.040 |
Why?
| | Temperature | 1 | 2022 | 669 | 0.040 |
Why?
| | Rupture, Spontaneous | 1 | 1998 | 15 | 0.040 |
Why?
| | Postprandial Period | 1 | 2019 | 111 | 0.040 |
Why?
| | Central Nervous System Depressants | 1 | 1999 | 89 | 0.040 |
Why?
| | Videotape Recording | 1 | 2018 | 39 | 0.040 |
Why?
| | Manikins | 1 | 2018 | 35 | 0.040 |
Why?
| | Analysis of Variance | 1 | 2001 | 1320 | 0.040 |
Why?
| | Sorption Detoxification | 1 | 1998 | 2 | 0.040 |
Why?
| | Immunosuppressive Agents | 1 | 2004 | 854 | 0.040 |
Why?
| | Ambulatory Care | 1 | 2023 | 582 | 0.040 |
Why?
| | Dietary Proteins | 1 | 2019 | 136 | 0.040 |
Why?
| | Cholinesterase Inhibitors | 1 | 1998 | 38 | 0.040 |
Why?
| | North America | 1 | 1999 | 306 | 0.040 |
Why?
| | Laparotomy | 1 | 1998 | 115 | 0.040 |
Why?
| | Recombinant Proteins | 1 | 2021 | 1357 | 0.030 |
Why?
| | Feedback | 1 | 2018 | 179 | 0.030 |
Why?
| | Cardiomyopathies | 1 | 2001 | 330 | 0.030 |
Why?
| | Lipids | 1 | 2022 | 689 | 0.030 |
Why?
| | Central Nervous System | 1 | 1999 | 265 | 0.030 |
Why?
| | Triglycerides | 1 | 2019 | 514 | 0.030 |
Why?
| | Cross-Over Studies | 1 | 2019 | 578 | 0.030 |
Why?
| | Immunoglobulin G | 1 | 2001 | 900 | 0.030 |
Why?
| | Maternal Health Services | 1 | 2019 | 103 | 0.030 |
Why?
| | Socioeconomic Factors | 2 | 2015 | 1306 | 0.030 |
Why?
| | Bipolar Disorder | 1 | 1999 | 276 | 0.030 |
Why?
| | Registries | 2 | 2010 | 2135 | 0.030 |
Why?
| | Oxidation-Reduction | 1 | 2019 | 1086 | 0.030 |
Why?
| | Dialysis | 1 | 2015 | 18 | 0.030 |
Why?
| | Centrifugation | 1 | 2015 | 27 | 0.030 |
Why?
| | Hallucinogens | 1 | 2017 | 112 | 0.030 |
Why?
| | Tennessee | 1 | 1994 | 52 | 0.030 |
Why?
| | Observation | 1 | 2014 | 56 | 0.030 |
Why?
| | Hematocrit | 1 | 1994 | 104 | 0.030 |
Why?
| | International Classification of Diseases | 1 | 2015 | 138 | 0.030 |
Why?
| | Program Evaluation | 1 | 2018 | 928 | 0.030 |
Why?
| | Syndrome | 1 | 2015 | 378 | 0.030 |
Why?
| | Anesthetics, Local | 1 | 2014 | 101 | 0.030 |
Why?
| | Warfare | 1 | 2014 | 83 | 0.030 |
Why?
| | Erythropoietin | 1 | 1994 | 98 | 0.030 |
Why?
| | Injections, Intralesional | 1 | 2013 | 35 | 0.030 |
Why?
| | Protein Binding | 1 | 2020 | 2239 | 0.030 |
Why?
| | Hospitals, Veterans | 1 | 1994 | 255 | 0.030 |
Why?
| | Salicylates | 1 | 2013 | 29 | 0.020 |
Why?
| | Urinalysis | 1 | 2013 | 77 | 0.020 |
Why?
| | Long QT Syndrome | 1 | 2013 | 70 | 0.020 |
Why?
| | Nursing Staff, Hospital | 1 | 1994 | 160 | 0.020 |
Why?
| | Hemoglobins | 1 | 1994 | 361 | 0.020 |
Why?
| | Iron | 1 | 1994 | 323 | 0.020 |
Why?
| | Therapeutic Irrigation | 1 | 2012 | 79 | 0.020 |
Why?
| | Receptors, Opioid, mu | 1 | 2012 | 70 | 0.020 |
Why?
| | Agranulocytosis | 1 | 2011 | 32 | 0.020 |
Why?
| | Vasculitis, Leukocytoclastic, Cutaneous | 1 | 2011 | 8 | 0.020 |
Why?
| | False Negative Reactions | 1 | 2011 | 61 | 0.020 |
Why?
| | Cytochrome P-450 Enzyme System | 1 | 2012 | 159 | 0.020 |
Why?
| | Leukoencephalopathies | 1 | 2011 | 19 | 0.020 |
Why?
| | Fluid Therapy | 1 | 2012 | 138 | 0.020 |
Why?
| | Computer Simulation | 1 | 2015 | 1015 | 0.020 |
Why?
| | Insulin Resistance | 1 | 2019 | 1225 | 0.020 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 2011 | 136 | 0.020 |
Why?
| | Toothache | 1 | 2010 | 5 | 0.020 |
Why?
| | Models, Theoretical | 1 | 1994 | 585 | 0.020 |
Why?
| | Immunoassay | 1 | 2011 | 113 | 0.020 |
Why?
| | Quality of Health Care | 1 | 2015 | 658 | 0.020 |
Why?
| | Drug Administration Routes | 1 | 2010 | 41 | 0.020 |
Why?
| | Disease Outbreaks | 1 | 2014 | 419 | 0.020 |
Why?
| | Insurance Coverage | 1 | 2012 | 237 | 0.020 |
Why?
| | Injections, Intravenous | 1 | 2010 | 202 | 0.020 |
Why?
| | Neurologic Examination | 1 | 2010 | 128 | 0.020 |
Why?
| | Patient Education as Topic | 1 | 1994 | 778 | 0.020 |
Why?
| | Age Distribution | 1 | 2010 | 395 | 0.020 |
Why?
| | Polymorphism, Genetic | 1 | 2012 | 625 | 0.020 |
Why?
| | Intestines | 1 | 2012 | 357 | 0.020 |
Why?
| | Kidney Failure, Chronic | 1 | 1994 | 596 | 0.020 |
Why?
| | Safety | 1 | 2010 | 356 | 0.020 |
Why?
| | Ethanol | 1 | 2012 | 629 | 0.020 |
Why?
| | Precision Medicine | 1 | 2012 | 434 | 0.020 |
Why?
| | Regression Analysis | 1 | 2010 | 1020 | 0.020 |
Why?
| | Seasons | 1 | 2010 | 546 | 0.020 |
Why?
| | Bilirubin | 1 | 2007 | 90 | 0.020 |
Why?
| | Disease Management | 1 | 2011 | 633 | 0.020 |
Why?
| | Pulse | 1 | 2006 | 26 | 0.020 |
Why?
| | Genotype | 1 | 2012 | 1859 | 0.020 |
Why?
| | Blastomycosis | 1 | 2006 | 11 | 0.020 |
Why?
| | Clinical Competence | 1 | 2014 | 1202 | 0.020 |
Why?
| | Contraindications | 1 | 2006 | 85 | 0.020 |
Why?
| | Metabolomics | 1 | 2012 | 704 | 0.020 |
Why?
| | Biopsy, Fine-Needle | 1 | 2006 | 70 | 0.020 |
Why?
| | Amyloidosis | 1 | 2006 | 49 | 0.020 |
Why?
| | Coronary Circulation | 1 | 2006 | 136 | 0.020 |
Why?
| | Electric Countershock | 1 | 2006 | 107 | 0.020 |
Why?
| | European Union | 1 | 2005 | 12 | 0.020 |
Why?
| | Fever | 1 | 2007 | 308 | 0.010 |
Why?
| | Disaster Planning | 1 | 2006 | 97 | 0.010 |
Why?
| | Emergencies | 1 | 2006 | 179 | 0.010 |
Why?
| | Infant, Newborn | 2 | 2007 | 6275 | 0.010 |
Why?
| | Administration, Inhalation | 1 | 2006 | 596 | 0.010 |
Why?
| | United States Food and Drug Administration | 1 | 2005 | 212 | 0.010 |
Why?
| | Up-Regulation | 1 | 2007 | 859 | 0.010 |
Why?
| | Pharmaceutical Preparations | 1 | 2006 | 178 | 0.010 |
Why?
| | Renal Insufficiency | 1 | 2006 | 169 | 0.010 |
Why?
| | Swine | 1 | 2006 | 806 | 0.010 |
Why?
| | Mice, Inbred ICR | 1 | 2004 | 119 | 0.010 |
Why?
| | Brain Injuries | 1 | 2009 | 502 | 0.010 |
Why?
| | Lupus Nephritis | 1 | 2004 | 67 | 0.010 |
Why?
| | Phenotype | 1 | 2012 | 3166 | 0.010 |
Why?
| | In Vitro Techniques | 1 | 2004 | 1093 | 0.010 |
Why?
| | Papillary Muscles | 1 | 2001 | 13 | 0.010 |
Why?
| | Models, Cardiovascular | 1 | 2001 | 197 | 0.010 |
Why?
| | Miosis | 1 | 1999 | 4 | 0.010 |
Why?
| | Blood Pressure | 1 | 2006 | 1748 | 0.010 |
Why?
| | Pupil | 1 | 1999 | 22 | 0.010 |
Why?
| | Hemodynamics | 1 | 2004 | 1100 | 0.010 |
Why?
| | Chronic Disease | 1 | 2004 | 1816 | 0.010 |
Why?
| | Algorithms | 1 | 2004 | 1763 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 2001 | 2520 | 0.010 |
Why?
| | Rats | 1 | 2001 | 5629 | 0.010 |
Why?
| | Neoplasms | 1 | 2006 | 2741 | 0.010 |
Why?
|
|
Heard's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|